Payload Information
General Information of This Payload
| Payload ID | PAY0NSWQE |
|||||
|---|---|---|---|---|---|---|
| Name | P2 payload |
|||||
| Synonyms |
P2 payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C41H43ClN6O3 |
|||||
| Isosmiles | CN1C(C2=C(C(N3CC(C=CC=C4)=C4C[C@@]3([H])CCCN(C)C)=O)C=CC(Cl)=C2)=CC(C(N(C(C=C5C#N)=C(N5C)C)C6=CC=C(O)C=C6)=O)=C1C |
|||||
| InChI |
InChI=1S/C41H43ClN6O3/c1-26-36(41(51)48(31-14-16-34(49)17-15-31)38-22-33(24-43)45(5)27(38)2)23-39(46(26)6)37-21-30(42)13-18-35(37)40(50)47-25-29-11-8-7-10-28(29)20-32(47)12-9-19-44(3)4/h7-8,10-11,13-18,21-23,32,49H,9,12,19-20,25H2,1-6H3/t32-/m1/s1
|
|||||
| InChIKey |
GPWGHMGTTWWDOY-JGCGQSQUSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
703.287 |
Polar area |
97.74 |
||
Complexity |
2159.84543 |
xlogp Value |
7.76552 |
|||
Heavy Count |
51 |
Rot Bonds |
9 |
|||
Hbond acc |
7 |
Hbond Donor |
1 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
NY920-P1-L12-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.037 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.217 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.305 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.38 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 1 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 5 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
NY920-P1-L19-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.037 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.06 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.146 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.16 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.216 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.407 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 10 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L19-P2 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L18-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.118 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L18-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L17-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.122 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L17-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.238 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L32-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.247 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L32-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||